机译:循环血管内皮生长因子的动态 - 从转移或复发性宫颈癌患者中预测抗血管生成胞嘧啶的益处
Division of Cancer SciencesUniversity of Manchester Manchester Academic Health Science;
Clinical &
Experimental Pharmacology Group Cancer Research UK Manchester Institute and Manchester;
Clinical &
Experimental Pharmacology Group Cancer Research UK Manchester Institute and Manchester;
Clinical &
Experimental Pharmacology Group Cancer Research UK Manchester Institute and Manchester;
Division of Cancer SciencesUniversity of Manchester Christie Hospital NHS Foundation Trust;
Department of Cancer StudiesUniversity of LeicesterLeicester UK;
Cancer Research UK Clinical Trials Unit Institute of Cancer SciencesUniversity of GlasgowGlasgow UK;
Christie Hospital NHS TrustManchester UK;
Cancer Research UK Clinical Trials Unit Institute of Cancer SciencesUniversity of GlasgowGlasgow UK;
Cancer Research UK Clinical Trials Unit Institute of Cancer SciencesUniversity of GlasgowGlasgow UK;
Cancer Research UK Clinical Trials Unit Institute of Cancer SciencesUniversity of GlasgowGlasgow UK;
Clinical &
Experimental Pharmacology Group Cancer Research UK Manchester Institute and Manchester;
Division of Cancer SciencesUniversity of Manchester Christie Hospital NHS Foundation Trust;
angiogenesis; cediranib; cervical cancer; CIRCCa trial; response biomarker; vascular endothelial growth factor;
机译:循环血管内皮生长因子的动态 - 从转移或复发性宫颈癌患者中预测抗血管生成胞嘧啶的益处
机译:浸润前,浸润和复发宫颈癌中的循环血管内皮生长因子及其可溶性受体。
机译:Cediranib是一种血管内皮生长因子受体激酶的口服抑制剂,是复发性上皮性卵巢癌,输卵管癌和腹膜癌的活性药物。
机译:褪黑素调节辐照大鼠颈脊髓中“血管内皮生长因子”基因的表达
机译:抗血管生成癌治疗的策略:利用血管内皮生长因子(VEGF)在肿瘤生长和内皮细胞存活中的作用。
机译:循环血管内皮生长因子的动态 - 从转移或复发性宫颈癌患者中预测抗血管生成胞嘧啶的益处
机译:循环血管内皮生长因子的动态 - 从转移或复发性宫颈癌患者中预测抗血管生成胞嘧啶的益处